Friday, December 19, 2025
News

Medicamen Organics Limited Reports Robust Growth in FY25: Revenue Up 51%, PAT Doubles in H2

SocialTwist Tell-a-Friend    Print this Page   COMMENT

| June 4, 2025 3:44:12 PM IST
VMPL

New Delhi [India], June 4: Medicamen Organics Limited has announced impressive financial results for FY25, showcasing strong performance across key metrics. The company reported a 51% year-on-year surge in revenue from operations, reaching Rs3,818.77 lakhs. Profit After Tax (PAT) witnessed a remarkable 101% growth in the second half of the fiscal year, while the company's net worth nearly doubled to Rs3,048.07 lakhs, reflecting solid financial health and consistent operational efficiency.

Highlights:

-Revenue increased due to a significant export presence in African, CIS, and Southeast Asian countries, being registered in 13 countries.

-Medicamen Organics Limited has identified significant market potential in:

Rising consumer preference for natural, science-backed, and ethically produced beauty products Increasing demand across Tier I and II cities for gender-neutral and inclusive personal care

The convergence of beauty, wellness, and lifestyle, offering cross-category synergies

- Global footprint and a strategic focus on expanding their international market presence.

- Manufacturing a wide range of pharmaceutical dosage forms including tablets, capsules, oral liquids, ointments, gels, syrups, suspensions, and dry powders.

- Strong relationships with customers and repeat orders. A loyal customer base and recurring business contribute to consistent and growing revenue streams.

Reflecting on the company's FY25 performance, Mr. Bal Kishan Gupta, Chairman and Managing Director of Medicamen Organics Limited, stated: "We are pleased to announce our formal entry into the cosmetics and personal care industry, through our subsidiary Grande Etiole Pharmaceuticals Limited, marking a significant milestone in its long-term growth and our diversification strategy. Our product portfolio consists of 84 products. We operate under different brand names across the globe. Our business is diversified in terms of geographies and therapeutic areas within the pharmaceutical industry. In terms of geographical diversity, we have marked our presence in India and we have registrations for manufacturing products as approved in international markets in countries like Congo, Benin, Togo, Senegal, Burkina Faso, Philippines, Myanmar, Mozambique, Togo, Burundi, Kyrgyzstan, Kenya. Our diversified revenue base enables us to mitigate the risk of income concentration by spreading revenue across multiple sources and opens opportunities to new prospects of growth."

(ADVERTORIAL DISCLAIMER: The above press release has been provided by VMPL. ANI will not be responsible in any way for the content of the same)

 
  LATEST COMMENTS (0)
POST YOUR COMMENT
Comments Not Available
 
POST YOUR COMMENT
 
 
TRENDING TOPICS
 
 
CITY NEWS
MORE CITIES
 
 
 
MORE BUSINESS NEWS
India-Oman CEPA to boost trade, investme...
Spotlight's Inter School Alumni golf tou...
buildAhome Achieves Landmark Milestone o...
Sanskriti University Receives ET Young I...
IIM Indore Launches Executive Programme ...
Stock market snaps four-day losing strea...
More...
 
INDIA WORLD ASIA
'Publicly apologise': SP MP Iqra Hasan c...
Maharashtra: Massive fire breaks out in ...
JNU student Najeeb's mother moves Delhi ...
District-level programmes to be held acr...
Impossible to change BMIC project in vie...
UP: Senior Deputy Election Commissioner ...
More...    
 
 Top Stories
With India-EU trade pact talks in "... 
ED flags 'grave legal errors' in Na... 
Pakistan using transnational repres... 
Thailand Tennis Masters to serve up... 
Hardik Pandya completes 2000 runs i... 
Maharashtra CM Devendra Fadnavis fe... 
Shikhar Dhawan launches residential... 
CBI Court sentences 4 years impriso...